Von dem Buch Handbook of HER2-Targeted Agents in Breast Cancer haben wir 4 gleiche oder sehr ähnliche Ausgaben identifiziert!
Falls Sie nur an einem bestimmten Exempar interessiert sind, können Sie aus der folgenden Liste jenes wählen, an dem Sie interessiert sind:
100%: Ricardo H. Alvarez; Javier Cortés; Mary Falzon; Michael Gandy; Luca Gianni: Handbook of HER2-Targeted Agents in Breast Cancer (ISBN: 9783319282169) 2016, in Deutsch, auch als eBook.Nur diese Ausgabe anzeigen…
100%: Ricardo H Alvarez; Javier Cortés; Leticia Mattos-Arruda; Mary Falzon; Angelica Fasolo; Michael Gandy; Luca Gianni; Nadia Harbeck: Handbook of HER2-targeted agents in breast cancer (ISBN: 9781907673931) in Englisch, Taschenbuch.Nur diese Ausgabe anzeigen…
100%: Ricardo H Alvarez; Javier Cortés; Leticia Mattos-Arruda; Mary Falzon; Angelica Fasolo; Michael Gandy; Luca Gianni; Nadia Harbeck: Handbook of HER2-targeted agents in breast cancer (ISBN: 9781907673948) in Englisch, auch als eBook.Nur diese Ausgabe anzeigen…
100%: Alvarez, Ricardo; Cortes, Javier; Falzon, Mary; Gianni, Luca; Harbeck, Nadia; Piccart, Martine: Handbook of HER2-Targeted Agents in Breast Cancer (ISBN: 9783319282145) 2016, in Deutsch, Taschenbuch.Nur diese Ausgabe anzeigen…
Handbook of HER2-Targeted Agents in Breast Cancer - 14 Angebote vergleichen
Bester Preis: € 1,83 (vom 12.03.2019)1
Gianni, Luca; Alvarez, Ricardo H; Corts, Javier; Falzon, Mary; Fasolo, Angelica; Gandy, Michael; Harbeck, Nadia; Piccart, Ma
Handbook of HER2-targeted agents in breast cancer
EN NW EBISBN: 9781907673931 bzw. 1907673938, in Englisch, Springer Healthcare Ltd. neu, E-Book.
Lieferung aus: Vereinigte Staaten von Amerika, Ebook for download.
Medicine, This book offers a concise and accessible survey of the field, including an overview of HER2-testing, a review of our current understanding of the biology of the HER2 pathway and the rationale for targeting it in early-stage and advanced breast cancer. eBook.
Medicine, This book offers a concise and accessible survey of the field, including an overview of HER2-testing, a review of our current understanding of the biology of the HER2 pathway and the rationale for targeting it in early-stage and advanced breast cancer. eBook.
2
Ricardo H Alvarez, Javier Cortés, Leticia Mattos-Arruda, Mary Falzon, Angelica Fasolo, Michael Gandy
Handbook of HER2-targeted agents in breast cancer
EN NW EB DLISBN: 9781907673948 bzw. 1907673946, in Englisch, Springer-Verlag, neu, E-Book, elektronischer Download.
Lieferung aus: Deutschland, E-Book zum Download.
"Breast cancer is the most frequently diagnosed cancer and the leading cause of cancer death in women worldwide, accounting for nearly a quarter of the total new cancer cases each year. Of these cases, approximately 15-25% overexpress HER2, a transmembrane RTK kinase that is associated with aggressive tumor growth and poor outcomes. However, in the past decade, survival rates of patients with HER-positive breast cancer have significantly improved due to increased screening, HER2 testing, and breakthrough HER2-targeted drug therapies. Handbook of HER2-Targeted Agents in Breast Cancer provides oncologists, primary care physicians, trainees and other healthcare providers with a concise, accessible, and up-to-date survey of the field, including a review of our current understanding of the biology of the HER2 pathway and the rationale for targeting it in early-stage and advanced breast cancer, an overview of HER2-testing, and evidence-based discussions of available HER2-targeted regimens in the adjuvant and metastatic settings. This book has been written by a collection of some of the foremost experts in the breast cancer field. Dr Ricardo Alvarez is an Assistant Professor in the Department of Breast Medical Oncology at the University of Texas MD Anderson Cancer Center. Dr Javier Cortes is Deputy Director of the Breast Cancer Program, Head of the Breast Cancer and Melanoma Group in the Oncology Department of Vall dHebron University Hospital. Dr Mary Falzon is Consultant Histo/Cytopathologist and Divisional Clinical Director for University College London Hospitals in London, UK. Michael Gandy is Head of Clinical and Research Services at University College London Advanced Diagnostics in London, UK. Dr Luca Gianni is the Director of the Department of Medical Oncology at the Hospital San Raffaele in Milan, Italy. Professor Nadia Harbeck is Head of the Breast Center at the University of Munich, Germany and heads the Oncological Therapy and Clinical Trials Unit in Obstetrics and Gynecology. Professor Martine Piccart is Professor of Oncology at the Université Libre de Bruxelles and Director of Medicine at the Jules Bordet Institute, in Brussels, Belgium.
"Breast cancer is the most frequently diagnosed cancer and the leading cause of cancer death in women worldwide, accounting for nearly a quarter of the total new cancer cases each year. Of these cases, approximately 15-25% overexpress HER2, a transmembrane RTK kinase that is associated with aggressive tumor growth and poor outcomes. However, in the past decade, survival rates of patients with HER-positive breast cancer have significantly improved due to increased screening, HER2 testing, and breakthrough HER2-targeted drug therapies. Handbook of HER2-Targeted Agents in Breast Cancer provides oncologists, primary care physicians, trainees and other healthcare providers with a concise, accessible, and up-to-date survey of the field, including a review of our current understanding of the biology of the HER2 pathway and the rationale for targeting it in early-stage and advanced breast cancer, an overview of HER2-testing, and evidence-based discussions of available HER2-targeted regimens in the adjuvant and metastatic settings. This book has been written by a collection of some of the foremost experts in the breast cancer field. Dr Ricardo Alvarez is an Assistant Professor in the Department of Breast Medical Oncology at the University of Texas MD Anderson Cancer Center. Dr Javier Cortes is Deputy Director of the Breast Cancer Program, Head of the Breast Cancer and Melanoma Group in the Oncology Department of Vall dHebron University Hospital. Dr Mary Falzon is Consultant Histo/Cytopathologist and Divisional Clinical Director for University College London Hospitals in London, UK. Michael Gandy is Head of Clinical and Research Services at University College London Advanced Diagnostics in London, UK. Dr Luca Gianni is the Director of the Department of Medical Oncology at the Hospital San Raffaele in Milan, Italy. Professor Nadia Harbeck is Head of the Breast Center at the University of Munich, Germany and heads the Oncological Therapy and Clinical Trials Unit in Obstetrics and Gynecology. Professor Martine Piccart is Professor of Oncology at the Université Libre de Bruxelles and Director of Medicine at the Jules Bordet Institute, in Brussels, Belgium.
3
Handbook of Her2-Targeted Agents in Breast Cancer
EN NWISBN: 9781907673931 bzw. 1907673938, in Englisch, Springer Healthcare, neu.
Lieferung aus: Vereinigtes Königreich Großbritannien und Nordirland, in-stock.
"Breast cancer is the most frequently diagnosed cancer and the leading cause of cancer death in women worldwide, accounting for nearly a quarter of the total new cancer cases each year. Of these cases, approximately 15 25% overexpress HER2, a transmembrane RTK kinase that is associated with aggressive tumor growth and poor outcomes. However, in the past decade, survival rates of patients with HER-positive breast cancer have significantly improved due to increased screening, HER2 testing, and breakthrough HER2-targeted drug therapies. Handbook of HER2-Targeted Agents in Breast Cancer provides oncologists, primary care physicians, trainees and other healthcare providers with a concise, accessible, and up-to-date survey of the field, including a review of our current understanding of the biology of the HER2 pathway and the rationale for targeting it in early-stage and advanced breast cancer, an overview of HER2-testing, and evidence-based discussions of available HER2-targeted regimens in the adjuvant and metastatic settings.
"Breast cancer is the most frequently diagnosed cancer and the leading cause of cancer death in women worldwide, accounting for nearly a quarter of the total new cancer cases each year. Of these cases, approximately 15 25% overexpress HER2, a transmembrane RTK kinase that is associated with aggressive tumor growth and poor outcomes. However, in the past decade, survival rates of patients with HER-positive breast cancer have significantly improved due to increased screening, HER2 testing, and breakthrough HER2-targeted drug therapies. Handbook of HER2-Targeted Agents in Breast Cancer provides oncologists, primary care physicians, trainees and other healthcare providers with a concise, accessible, and up-to-date survey of the field, including a review of our current understanding of the biology of the HER2 pathway and the rationale for targeting it in early-stage and advanced breast cancer, an overview of HER2-testing, and evidence-based discussions of available HER2-targeted regimens in the adjuvant and metastatic settings.
4
Handbook of HER2-targeted agents in breast cancer
EN NWISBN: 9781907673931 bzw. 1907673938, in Englisch, Springer Healthcare Ltd. neu.
Lieferung aus: Kanada, In Stock, plus shipping.
Die Beschreibung dieses Angebotes ist von geringer Qualität oder in einer Fremdsprache. Trotzdem anzeigen
Die Beschreibung dieses Angebotes ist von geringer Qualität oder in einer Fremdsprache. Trotzdem anzeigen
5
Handbook of HER2-targeted agents in breast cancer
EN PB NWISBN: 9781907673931 bzw. 1907673938, in Englisch, Springer Healthcare Ltd. Taschenbuch, neu.
Lieferung aus: Vereinigte Staaten von Amerika, In Stock.
Die Beschreibung dieses Angebotes ist von geringer Qualität oder in einer Fremdsprache. Trotzdem anzeigen
Die Beschreibung dieses Angebotes ist von geringer Qualität oder in einer Fremdsprache. Trotzdem anzeigen
6
Handbook of HER2-Targeted Agents in Breast Cancer (2016)
DE NW EBISBN: 9783319282169 bzw. 3319282166, in Deutsch, Springer, neu, E-Book.
Lieferung aus: Schweiz, Sofort per Download lieferbar.
Die Beschreibung dieses Angebotes ist von geringer Qualität oder in einer Fremdsprache. Trotzdem anzeigen
Die Beschreibung dieses Angebotes ist von geringer Qualität oder in einer Fremdsprache. Trotzdem anzeigen
7
Handbook of HER2-Targeted Agents in Breast Cancer (2016)
DE NW EBISBN: 9783319282169 bzw. 3319282166, in Deutsch, Springer, neu, E-Book.
Lieferung aus: Deutschland, Sofort per Download lieferbar.
Die Beschreibung dieses Angebotes ist von geringer Qualität oder in einer Fremdsprache. Trotzdem anzeigen
Die Beschreibung dieses Angebotes ist von geringer Qualität oder in einer Fremdsprache. Trotzdem anzeigen
8
Handbook of HER2-Targeted Agents in Breast Cancer
DE NW EB DLISBN: 9783319282169 bzw. 3319282166, in Deutsch, Springer International Publishing, neu, E-Book, elektronischer Download.
Lieferung aus: Deutschland, Versandkostenfrei.
Die Beschreibung dieses Angebotes ist von geringer Qualität oder in einer Fremdsprache. Trotzdem anzeigen
Die Beschreibung dieses Angebotes ist von geringer Qualität oder in einer Fremdsprache. Trotzdem anzeigen
9
Ricardo H Alvarez; Javier Cortés; Mary Falzon; Michael Gandy; Luca Gianni; Nadia Harbeck; Martine Piccart
Handbook of HER2-Targeted Agents in Breast Cancer
DE NW EB DLISBN: 9783319282169 bzw. 3319282166, in Deutsch, Springer Shop, neu, E-Book, elektronischer Download.
Lieferung aus: Italien, Lagernd, zzgl. Versandkosten.
Die Beschreibung dieses Angebotes ist von geringer Qualität oder in einer Fremdsprache. Trotzdem anzeigen
Die Beschreibung dieses Angebotes ist von geringer Qualität oder in einer Fremdsprache. Trotzdem anzeigen
Lade…